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Abstract
Acute pancreatitis (AP) is common gastrointestinal 
disease of varied aetiology. The most common cause 
of AP is gallstones, followed by alcohol abuse as an 
independent risk factor. With the increased need for 
invasive techniques to treat pancreatic and bile duct 
pathologies such as endoscopic retrograde cholan-
giopancreatography (ERCP), AP has emerged as the 
most frequent complication. While severe AP following 
ERCP is rare (0.5%), if it does develop it has a greater 
severity index compared to non-ERCP AP. Development 
of a mild form of AP after ERCP is not considered a 
clinically relevant condition. Differences in the clinical 
presentation and prognosis of the mild and severe 
forms have been found between non-ERCP AP and post-
endoscopic pancreatitis (PEP). It has been proposed 
that AP and PEP may also have different immunological 
responses to the initial injury. In this review, we 
summarise the literature on clinical and inflammatory 
processes in PEP vs  non-ERCP AP.
Key words: Acute pancreatitis; Endoscopic retrograde 
cholangiopancreatography; Post endoscopic retrograde 
cholangiopancreatography pancreatitis
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Core tip: Acute pancreatitis (AP) is the most frequent 
complication after endoscopic retrograde cholangio-
pancreatography (ERCP) and although low prevalence 
is found, if it develops it has greater severity index 
compared to non-ERCP AP. The differences in factors 
influencing appearance, clinical presentation and 
prognosis of ERCP induced and non ERCP induced AP 
were found, lead to opinion that mechanism by which 
they induce inflammation, may also be different. It 
would be of great importance to find immunological 
components that can distinguish patients with tendency 
to develop severe AP from patients with mild form, 
especially in ERCP induced AP where organ failure occurs 
half time earlier.
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INTRODUCTION
Acute pancreatitis (AP) is a common gastrointestinal 
disease with a reported incidence of 13-45 cases per 
100000 persons annually[1]. According to the revised 
Atlanta classification, diagnosis of AP requires two of 
three following features: upper abdominal pain of acute 
onset, often radiating through to the back; serum 
amylase or lipase activity greater than three-times the 
normal level; and findings on cross-sectional abdominal 
imaging consistent with AP[2]. The severity of AP can be 
divided into mild, moderately severe or severe forms 
based on the presence or absence of persistent organ 
failure and local and systemic complications (Table 1). 
The mild form of AP is characterised by inflammation 
and the synthesis of proinflammatory cytokines in the 
affected area. The moderate and severe forms are 
characterised by the release of proinflammatory mole-
cules into the circulation, causing systemic inflammatory 
response syndrome (SIRS)[3].
Gallstones are most common cause of AP, followed 
by alcohol abuse as an independent risk factor[2]. 
Invasive techniques used for the treatment of pan-
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creatic and bile duct pathologies, such as endoscopic 
retrograde cholangiopancreatography (ERCP), carry 
a certain risk of complications. The most frequent of 
these is AP. Large variations in the reported incidence 
and severity of post-endoscopic pancreatitis (PEP) has 
led to unobjective risk evaluation, mostly consisting of 
retrospective studies. Kochar et al[4] reported an overall 
PEP incidence of 9.7%, while in high-risk patients the 
incidence was 14.7%. It is important to record why 
ERCP is performed, whether for therapeutic or diagnostic 
reasons, as patients may have an underlying condition 
that may affect the incidence of complications[5]. Most 
records report increased PEP after therapeutic ERCP[6].
AP is a disease of varied aetiology. Each produces a 
similar disease pattern, indicating that they all converge 
at a common point to initiate a cascade of events re-
sulting in AP[7,8]. Messmann et al[5] found that people 
with AP are usually admitted to hospital several hours or 
even days after the initiation of symptoms. Therefore, it 
is impossible to determine the exact time of injury and 
initiation of the inflammatory phase. Instead, studies use 
PEP as a human model to examine the initial cytokine 
and acute-phase response in the first hours after 
initiation. It has been reported that PEP can serve as 
an ideal model for investigating the initial inflammatory 
phase in non-ERCP-induced AP. 
An alternate opinion is that AP and PEP may actually 
be different disorders. This assumption is based on the 
differences in clinical presentation and prognosis of the 
mild and severe forms[9,10]. The triggers for the two 
disorders differ, and consequently, the mechanism by 
which they induce inflammation may also differ[11].
CLINICAL PRESENTATION
Different clinical outcomes of non-ERCP-induced AP and 
PEP have been found in several studies[9,10,12] (Table 2). 
Patients that developed post-ERCP pancreatitis initially 
had a higher APACHE Ⅱ score (key prognostic factor 
in predicting mortality) compared to AP of other aetio-
logies[10]. The APACHE Ⅱ score takes approximately 48 
h to achieve a good predictive index. Therefore, whether 
this score represents a good method to differentiate 
initial disease severity prognosis (within 24 h), and if it 
can be reliably used to compare non-ERCP AP and PEP, 
remain questionable[9]. 
As mentioned earlier, severe AP following ERCP is 
rare (0.5%), but if it does develop, it does so with a 
greater severity index when compared to non-ERCP AP. 
Fung et al[10] reported that the extent of parenchymal 
necrosis is greater in PEP patients. There was also a 
higher rate of infected necrosis in the PEP group in their 
study. In PEP, the infection occurs earlier than in acute 
non-ERCP-induced pancreatitis. Due to small number of 
patients with ERCP induced acute necrotising pancreatitis 
(ANP) and low statistical power of their study, results 
should be interpreted with caution. All the same, these 
results should be taken into consideration, since the 
presence of infection and its extent is more important 
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Table 1  Severity of acute pancreatitis
for disease prognosis than pancreatic necrosis[10]. Organ 
failure develops early in the severe form of AP, either 
present at admission or 24 h later. In PEP, organ failure 
occurs twice as fast as in non-ERCP AP[3]. 
The mild form of ERCP-induced pancreatitis has a 
shorter and milder disease course with only a temporary 
increase in the level of enzymes in the blood (up to 
48 h), suggesting a non-specific pancreatic reaction to 
injury, not necessary inflammation. Patients with mild 
post-ERCP pancreatitis have been reported to have 
a significantly shorter duration of pain and need for 
analgesia and parenteral hydration. All patients involved 
in this study, indicated for ERCP, were studied after they 
had been discharged from hospital because the acute 
condition can influence the intensity of inflammation[9]. 
Studies on drug effectiveness on the prevention of 
post-ERCP AP use the reduction in total post-ERCP AP 
incidence as the final measurement. So far, results have 
shown a reduction in the mild form but not the severe 
form. The primary goal should be a reduced incidence of 
severe PEP, as the mild form is not a clinically relevant 
condition[13-16].
MECHANISM OF INJURY
Non-ERCP pancreatitis 
As previously mentioned, the most common causes of 
non-ERCP AP are gallstones and alcohol abuse[2]. The 
primary location of injury for both causes are acinar 
cells[17]. Gallstones lead to duct obstruction and blocking 
of acinar exocytosis, leading to the colocalization of 
zymogen and lysosomal granules and early activation of 
pancreatic enzymes. Alcohol leads to oxidative and non-
oxidative damage. The non-oxidative pathway involves 
increased levels fatty acid ethyl ester, whereas the 
oxidative pathway is characterised by the accumulation 
of acetaldehyde, acetate and NADH. Alcohol also 
modifies the intracellular redox state by diminishing the 
NAD/NADH ratio and increasing the lactate/pyruvate 
ratio, ultimately leading to metabolic alterations and 
acinar cell injury[18].
Post-endoscopic pancreatitis
The factors influencing PEP incidence are multifactorial. 
These include patient-related factors, operator-related 
factors and method-related factors. Patient-related 
factors involve age, sex, pre-existing pancreatitis, 
prior history of post-ERCP pancreatitis, sphincter of 
Oddi dysfunction, and small bile duct and pancreatic 
divisum. Operator-related factors are associated with 
the experience of the endoscopist. The method-related 
factors are the most important because in them lies the 
greatest possibility for controlled intervention. Method-
related factors cause mechanical injury a number of 
different ways. Combined operator and method- related 
factor as repeated and difficult papilla cannulation 
can lead to oedema and obstruction of free juice flow 
and sphincter of Oddi spasm. This mechanism may 
resemble the damage caused by gallstone obstruction. 
Furthermore, osmolarity and the ionic nature of the 
contrast media can cause chemical injury. Injecting 
contrast media are responsible for hydrostatic injury, 
which is one of the main causes of pancreatitis after 
ERCP[19]. Another factor is increased duct pressure, which 
can cause early activation of pancreatic enzymes[20]. 
However, microbiological factors related to contaminated 
endoscope and translocation from the intestines is not 
considered to play a major role.
INFLAMMATORY PROCESS
General
It is considered that the first pancreatic event, in any 
of these circumstances, occurs at the level of acinar 
cells[21]. Intrapancreatic trypsinogen activation and NFκB 
activation represent the two main initial triggers for 
AP[8,22]. Sah et al[22] reviewed studies that used animal 
models to show that NFκB activates and induces inflam-
mation without the need for trypsinogen activation. 
Therefore, these two events represent two independent 
cellular events. 
The early events in AP include inhibition of zymogen 
secretion, altered intracellular Ca2+ homeostasis that 
modifies pH values (Figure 1), intrapancreatic activation 
of trypsinogen and other zymogens and activation of 
cell death pathways (NFκB)[8,18].
The initial injury of the acinar cells caused by zymo-
gens is sterile[23] (Figure 2). 
Sterile inflammation requires two distinct signals 
through the activation of pattern recognition receptors 
(PRRs) (Figure 3). PRRs, like Toll like receptor (TLR) and 
NOD like receptor (NLR), are part of the innate immune 
response[23]. 
Randomised controlled trials have been used to 
study the use of allopurinol in the prevention of post-
ERCP AP. Allopurinol reduces the production of uric 
acid. Uric acid uses DAMPs (NLR receptors) to trigger 
an inflammatory response. These studies found that 
allopurinol decreases the incidence of post-ERCP AP[24,25], 
indicating that the innate immune cells play a role 
in AP after ERCP[21]. Shamoon et al[26] in their study, 
emphasise the importance of innate immune cells and 
derived inflammatory mediators as therapeutic targets 
in AP in early phase of the disease (24-48 h). 
The balance between pro- and anti-inflammatory 
immune response determines the prognosis in AP. A fall 
in the co-expression of HLA-DR on CD14+ monocytes is 
considered a standard laboratory indicator of compen-
satory anti-inflammatory immune response syndrome 
(CARS)[27]. The severe form of AP is frequently associated 
with immune suppression, which increases the risk 
Mild Absence of both (peri) pancreatic necrosis and organ failure
Moderate Presence of sterile (peri) pancreatic necrosis and transient 
organ failure
Severe Infected (peri) pancreatic necrosis or persistent organ failure
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of infection, organ failure and death[28]. Kylanpaa et 
al[3] reported that impaired cellular immunity causes 
complications related to infection in AP at a later stage 
of the disease. Furthermore, Testoni et al[12] reported 
that infection in PEP occurs during or immediately after 
the procedure. For this reason, infection in non-ERCP 
AP is considered a secondary event, while in PEP it is 
considered the primary event. 
IMMUNE COMPONENTS 
While the role of different cytokines in AP has been 
Table 2  Differences in post-endoscopic pancreatitis vs  non- endoscopic retrograde cholangiopancreatography induced acute 
pancreatitis clinical presentation
PEP non-ERCP-induced AP Conclusion
Fung et al[10]
ERCP-induced acute 
necrotising pancreatitis 
vs  ANP induced by 
other causes
Higher APACHE Ⅱ scores on admission Lower APACHE Ⅱ scores on admission ANP is more severe when ERCP-induced
More extensive pancreatic necrosis Less extensive pancreatic necrosis
Higher rate of infected necrosis Lower rate of infected necrosis
Testoni et al[12]
ERCP induced AP vs 
non ERCP induced AP
No statistical difference: severity of the pancreatitis 
mortality rate (double in severe PEP)
hospitalisation
In mild form serum amylase fell 50% in 
38.9 h.
Peak serum amylase halved within 48 h in 
92%
In mild form serum amylase fell 50% in 46, 
4 h.
Peak serum amylase halved within 48 h in 
73.6%
Statistical difference (P < 0.001)
Mild form of PEP a sort of pancreatic 
reaction, instead of true episode of acute 
pancreatitis
Abid et al[9]
M i l d  f o r m :  E R C P 
induced AP vs  non 
ERCP induced AP
Shorter duration of pain; Shorter time of 
intravenous hydration; Shorter time to 
resumption of oral diet; Shorter hospital 
stay (P < 0.001)
ERCP-induced AP mild attacks run a 
significantly shorter and milder course 
than non-ERCP related mild attacks
PEP: Post-endoscopic pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography; AP: Acute pancreatitis.
Increase in Ca2+ Low pH Activation of lysosomal hydrolase-cathepsin B
Early trypsinogen 
activatio
Figure 1  Altered Ca2+ homeostasis- change from physiologic intracellular transient Ca2+ spikes to pathologically sustained global Ca2+ rise, can lead to 
significantly lower pH values and cause early enzyme activation.
Release of 
intracellular 
contentsAcinar cell 
necrosisSterile initial
injury
DAMPs-key
determinant of 
further pancreatic injury
Figure 2  Sterile injury causes acinar cell necrosis, the release of intracellular contents, and activation of damage-associated molecular patterns that further 
determine pancreatic injury.
TOLL-like receptor superfamily (TLR) P2X7 receptor and NOD-like receptors (NLRs)
Induction of gene expression 
of proinflammatory cytokines
( pro- IL 1β, pro- IL 18 )
Activation of cytosolic complex 
inflammasome
Controls maturation of caspase 1
Interleukin converting enzyme (ICE) 
regulates conversion of proinflammatory 
cytokines into mature forms
Figure 3  Activation of pattern recognition receptors.
Plavsic I et al . Differences between ERCP-induced and non-ERCP-induced acute pancreatitis
263 October 16, 2018|Volume 10|Issue 10|WJGE|www.wjgnet.com
extensively studied, the role of cellular immunity is 
poorly evaluated[28]. Innate immune cells are the major 
leukocyte population in the inflamed pancreas[29]. 
Monocytes and macrophages
Monocytes and macrophages are the main inflammatory 
cell populations in AP, and both play active roles in AP 
progression. The production of proinflammatory factors 
like tumour necrosis factor (TNF)-α in pancreatic cell 
stimulates the activation of macrophages in distal 
organs including the peritoneum, spleen, liver and 
lungs. Monocyte chemoattractant protein (MCP)-1 
and macrophage migration inhibitory factor (MIF) play 
important roles in AP. Bhatia et al[30] reported that 
blocking MCP-1 synthesis reduces the severity of AP. 
Furthermore, antibodies against MIF improve survival in 
rats with AP[31]. The expression of HLA-DR on monocytes 
gives a good indication of monocyte function. In cases 
of immunosuppression, decreased monocyte HLA-DR 
expression predicts the development of organ failure[32]. 
Neutrophils
Neutrophils play a central role in the development of 
local and systemic complications, therefore, researchers 
have investigated the depletion of neutrophils as a 
therapeutic option for AP. Anti-neutrophil serum (ANS) 
exhibited a marked attenuation in intrapancreatic 
trypsin activation, ameliorated choline-deficient 
ethionine supplemented (CDE) diet-induced pancreatitis 
and completely prevented lung injury[33,34]. The de-
pletion of neutrophils associated with ANS did not 
influence macrophage infiltration, but it did decrease 
the number of lymphocytes in the pancreas[29].
T cells 
Progression of AP is accompanied by a change in the 
number and ratio of CD4+ and CD8+ lymphocytes[35]. 
CD4+ lymphocytes are especially important as they act 
as co-stimulators of macrophage activation via antigen 
presentation and the release of proinflammatory 
cytokines. They have been reported to have a direct 
cytotoxic effect on acinar cells through Fas ligand 
expression[36]. Depletion of CD4+ lymphocytes reduces 
the severity of AP[21]; however, CD4+ lymphocytes are 
a heterogeneous population and some release IL-22, 
which has an anti-inflammatory effect[37].
Natural killer cells
Natural killer (NK) cells are predominantly studied in 
response to infection and immunosurveillance against 
tumours. They are part of the innate immune system, 
giving them the ability to respond without prior sen-
sitisation. They also carry certain abilities of adaptive 
immunity, as they are primed during development, their 
receptors can exhibit antigen specificity, they undergo 
clonal expansion during infection and generate long-
lived memory cells[38]. Natural killer cells can undergo 
clonal-like expansion through specific and non-specific 
immune responses. While the specific response oc-
curs via interaction of their activating receptors with 
viral antigens, the non-specific response is driven by 
the production of cytokines and proliferation following 
exposure to proinflammatory cytokines in the absence 
of TCR signals and co-stimulation[39,40]. Natural killer 
cells have immunological memory, which enables them 
to react faster and more aggressively in familiar sur-
roundings. The most important cytokines produced by 
NK cells after activation are TNF-α and IFN-γ[41]. It is 
thought that NK cells that produce proinflammatory 
cytokines can contribute to dysregulation of the immune 
response as seen in sepsis[42]. The cytokine IL-15 pays 
a role in the maintenance of NK cells. The half-life of 
mature NK cells is about 1 wk, but in the absence of 
IL-15 they disappear in 48 h. These cells can also serve 
as an immunotherapeutic target.
Dabrowski et al[28] reported significant depletion 
of the NK cell population on the first day of severe 
AP, while there was no significant change in NK cell 
number in mild AP. These findings are consistent with 
the idea that severe forms of AP are related to immune 
suppression. Profound inhibition of innate cell immunity 
can be explained by the migration of NK cells and 
natural killer T (NKT) cells to the site of inflammation.
Natural killer T cells
Natural killer T cells are generally autoreactive and can 
recognise both exogenous and endogenous ligands. 
There are two types of NKT cells, type Ⅰ and type Ⅱ. 
Type Ⅰ is more prevalent in mice and can be either pa-
thogenic or protective, although they have a greater 
propensity to be pathogenic. Type Ⅱ is prevalent in 
humans, and predominantly protect against inflammation 
and autoimmune disease. Different self-antigens can 
stimulate type Ⅰ NKT cells, and some of these antigens 
are present at elevated levels during inflammation[43].
In patients with severe AP there is a reduction in the 
number of peripheral lymphocytes, especially monocytes 
and cytotoxic T lymphocytes[28,44].
Cytokines
The most important anti-inflammatory cytokine is 
interleukin (IL)-10. It down-regulates the production 
of proinflammatory cytokines and the expression of 
HLA-DR on monocytes. If the compensatory anti-
inflammatory response is too intense, however, it may 
lead to immunosuppression and complications including 
infection. The concentration of IL-10 is highest in the 
early phase of severe AP. As infection is considered to be 
one of the prognostic factors related to disease severity, 
IL-10 may be a promising predictive marker of organ 
failure[45]. There are conflicting reports for the use of 
IL-10 in the prevention of post-ERCP AP. In a randomised 
double-blind study, Deviere et al[46] showed a reduced 
incidence of post-ERCP AP after IL-10 usage, although 
this was not supported by a study by Dumot et al[47].
As a key proinflammatory mediator, IL-6 regulates 
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the synthesis of acute-phase proteins in the liver as 
well as macrophage-conditioned tissue damage[48]. It 
reaches its peak value 24-48 h after clinical expression. 
In necrotising pancreatitis, the peak levels of IL-6 
occur after 24 h[5]. Minkov et al[48] concluded that IL-6 
represents an independent factor for predicting severity 
in acute non-ERCP pancreatitis.
The highest values of C-reactive protein (CRP) are 
recorded after 48–72 h, which is later than that of IL-6[5]. 
Although CRP has been identified as a late marker in 
laboratory monitoring[49], Messman et al[5] found that 
both IL-6 and CRP peak earlier in patients with ANP. 
IL-1β-mediated signalling is required for full pan-
creatic and distal organ injury and inflammation[50], 
and is the pivotal inflammatory mediator in cell death 
associated with sterile inflammation[51]. Serum levels 
of IL-1β do not correlate with AP severity in humans, 
although it has been found that the values peak after 24 
h and are greater in patients with severe AP compared to 
mild AP[52]. In animal models, peak serum IL-1β precede 
peak serum IL-6 values[50,53]. It is possible that IL-1β is 
required for the induction of IL-6 production, which is 
strongly correlated with disease severity in humans[54]. 
IL-1β and TNF-α are considered the primary cytokines 
that initiate and propagate most of the consequences of 
the SIRS in AP[55,56]. IL-6 prevents the synthesis of IL-1β 
and TNF-α[57].
Kilciner et al[49] compared early changes (within 24 
h) in the serum levels of IL-2, IL-4, TNF-α and IL-6 in 
the development of post-ERCP pancreatitis. They used 
patients who underwent ERCP as well as a control 
group consisting of patients with non-ERCP AP caused 
by gallstones, drugs or alcohol. They found that IL-4, 
an anti-inflammatory cytokine, was significantly lower 
in post-ERCP and non-ERCP AP patients compared to 
patients who did not develop pancreatitis. The TNF-α 
level was not significantly different after 24 h in patients 
who developed PEP compared to those who did not 
develop pancreatitis after ERCP. After 24 h, the IL-6 
levels did not differ from the control group, but they 
were significantly higher compared to patients who did 
not go on to develop pancreatitis after ERCP.
The role of IL-18 may depend on the presence of 
other cytokines. It plays an important role in the local 
immune response to pancreatic injury[23], and can also be 
found in serum. It has been described to prime NK cells, 
and NK cells that were unable to receive IL-18 signals 
were found to have defective cytotoxicity and cytokine 
secretion after stimulation[38].
AP is the most frequent complication after the ERCP 
procedure. Although the incidence of AP after ERCP is 
low, it is reported to occur in 0.5% of patients, PEP has a 
greater severity index compared to non-ERCP AP[10]. As 
the mild form of PEP is not a clinically relevant condition, 
it would be useful to identify early markers to predict 
whether a patient will develop the severe form of PEP.
 The serial changes in amylase and lipase levels in 
patients without PEP suggest the existence of subclinical 
pancreatic damage. Messmann found that amylase 
and lipase levels increased equally among all patients 
after ERCP[5]. Amylase and lipase are released into 
the systemic circulation due to disturbed transport 
and increased ductal permeability; however, they are 
not thought to be responsible for inducing further in-
flammation. Based to these findings, we conclude that 
serum amylase values can’t serve as an adequate 
future therapeutic goal.
The role of cytokines, especially IL-10, IL-6 and 
TNF-α, have been extensively studied for the prediction 
of disease severity[45,48,55,56]. These cytokines can be 
used to predict the severity of PEP after 12-24 h; 
however, measurements taken 4 h after the procedure 
showed no significant difference between patients who 
developed PEP and those who did not develop PEP[51,58]. 
Further research on the initial inflammatory response 
is necessary, particularly as organ failure has been 
reported to occur earlier in severe forms of AP, either 
at admission or 14 h later. Furthermore, in PEP, organ 
failure occurs twice as fast than in non-ERCP AP[44]. 
Direct comparison of the initial inflammatory response 
between PEP and non-ERCP AP would be of significant 
importance to clarify these statements. Found difference 
in clinical response to initial injury might be explained 
by different initial immune response[59]. 
Infection is considered to be the most important 
prognostic factor for disease severity. Similarities bet-
ween cytokines and inflammatory mediators in sepsis 
and AP are often compared. Kjaergaard et al[60] reported 
that the expression of NKG2D receptors on NK cells and 
CD14 on monocytes can be valuable prognostic markers 
of an unbalanced immune response, and may predict 
a worse outcome for critically ill patients. Also, Guo et 
al[61] presented natural killer cells as critical to eliminate 
pathogens during the early phase of sepsis and prevent 
patients from developing secondary infection. We suggest 
that similar components should be used in PEP and non 
ERCP AP.
In addition to searching for adequate biomarkers 
to assess disease severity, it is our opinion that novel 
therapeutic strategies for both of these conditions lie in 
uncovering the immune pathways.
CONCLUSION
The most frequent complication after ERCP is AP. In most 
cases, it is not a clinically relevant condition, but in 0.5% 
of patients it has a greater severity index compared 
to non-ERCP AP. In severe PEP, infection occurs earlier 
than in acute non-ERCP-induced pancreatitis, and organ 
failure occurs twice as fast. Treatment of AP, regardless 
of the cause, is primarily supportive and implies a certain 
economic burden in the healthcare system worldwide. 
More thorough clarification of disease pathogenesis is 
needed, in order to find adequate immune target to 
predict and consequently prevent severe form of the 
disease. 
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